Amarantus Announces Commercialization Partnership
Post# of 30028
(Total Views: 391)
Posted On: 01/11/2019 5:18:07 AM
Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries
BY Canada NewsWire
— 5:00 AM ET 01/11/2019
NEW YORK, Jan. 11, 2019 /CNW/ - Amarantus Bioscience Holdings, Inc. ( AMBS Loading...) , a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, and IDEA Pharma Ltd (a UK-based path-to-market strategy and applied innovation consulting group), have announced a highly original partnership, to bring together Amarantus' innovative therapeutics and diagnostics portfolio with IDEA's industry-leading path-to-market expertise. IDEA, who have supported 8 of the 15 biggest biopharmaceutical launches in the past 3 years, will partner with Amarantus in a novel royalty-split model. The virtual Chief Commercial Officer partnership will provide multi-year commercial strategy to the Amarantus portfolio of companies, with royalties paid to IDEA following successful monetisation. The Amarantus/ IDEA Pharma partnership will run for 5 years, and be renewable upon mutual consent.
"The Amarantus portfolio is exciting and innovative, and we were keen to match that innovation with a model that incentivises successful commercialisation," said Mike Rea, CEO IDEA Pharma. "The traditional fee-for-service consulting model is one that rewards quantity of input over quality, and imports established ideas from large pharma. When you win together it drives the best behaviour and crucially, allows an early-stage company like Amarantus to benefit from the right strategic inputs early. We are especially excited about working with the organizations being established around each of Amarantus' pipeline products as we will be able to create value for Amarantus not only with its portfolio, but also with the complementary assets being aggregated within each of those organizations, beginning with Coeptis' recently approved product Consensi®."
"One of the key challenges for an early-stage biotech is to combine agility and innovation with world-class expertise, and the reassurance of experience," said Gerald Commissiong, CEO Amarantus. "A key area of focus for Amarantus is to maximize leading commercial competency that can both answer the 'what if' questions quickly and correctly - minimising cost, but maximising returns. This partnership will bring our subsidiaries cutting edge understanding of Commercial, incentivised for the long-term, which is hard to achieve in a traditional hiring strategy, or with fee-for-service partners. We believe this is the perfect blend of risk mitigation with maximisation of upside, and importantly for a biotech, we keep subsidiary overhead to a minimum."
BY Canada NewsWire
— 5:00 AM ET 01/11/2019
NEW YORK, Jan. 11, 2019 /CNW/ - Amarantus Bioscience Holdings, Inc. ( AMBS Loading...) , a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, and IDEA Pharma Ltd (a UK-based path-to-market strategy and applied innovation consulting group), have announced a highly original partnership, to bring together Amarantus' innovative therapeutics and diagnostics portfolio with IDEA's industry-leading path-to-market expertise. IDEA, who have supported 8 of the 15 biggest biopharmaceutical launches in the past 3 years, will partner with Amarantus in a novel royalty-split model. The virtual Chief Commercial Officer partnership will provide multi-year commercial strategy to the Amarantus portfolio of companies, with royalties paid to IDEA following successful monetisation. The Amarantus/ IDEA Pharma partnership will run for 5 years, and be renewable upon mutual consent.
"The Amarantus portfolio is exciting and innovative, and we were keen to match that innovation with a model that incentivises successful commercialisation," said Mike Rea, CEO IDEA Pharma. "The traditional fee-for-service consulting model is one that rewards quantity of input over quality, and imports established ideas from large pharma. When you win together it drives the best behaviour and crucially, allows an early-stage company like Amarantus to benefit from the right strategic inputs early. We are especially excited about working with the organizations being established around each of Amarantus' pipeline products as we will be able to create value for Amarantus not only with its portfolio, but also with the complementary assets being aggregated within each of those organizations, beginning with Coeptis' recently approved product Consensi®."
"One of the key challenges for an early-stage biotech is to combine agility and innovation with world-class expertise, and the reassurance of experience," said Gerald Commissiong, CEO Amarantus. "A key area of focus for Amarantus is to maximize leading commercial competency that can both answer the 'what if' questions quickly and correctly - minimising cost, but maximising returns. This partnership will bring our subsidiaries cutting edge understanding of Commercial, incentivised for the long-term, which is hard to achieve in a traditional hiring strategy, or with fee-for-service partners. We believe this is the perfect blend of risk mitigation with maximisation of upside, and importantly for a biotech, we keep subsidiary overhead to a minimum."
(10)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼